PDF(Pubmed)
Abstract：
Background: Nivolumab has been shown to improve the overall survival (OS) of patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, there is a need to identify factors associated with long-term survival (beyond 2 years) in these patients. This study investigated the relationship between pretreatment factors and long-term survival in patients with R/M HNSCC treated with nivolumab. Methods: Forty-nine patients with R/M HNSCC who were treated with nivolumab were retrospectively reviewed. Baseline characteristics, clinical data, and survival outcomes were evaluated. Univariate and multivariate analyses were performed to identify factors associated with long-term survival (OS ≥ 2 years). Results: The median OS in the overall cohort was 11.0 months, and the 2-year survival rate was 34.7%. Long-term survivors (OS ≥ 2 years) had significantly higher proportions of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of 0 or 1, serum albumin levels ≥ 3.5 g/dL, and neutrophil-to-eosinophil ratio (NER) < 32.0 compared to non-long-term survivors. On multivariate analysis, serum albumin levels ≥ 3.5 g/dL, in addition to ECOG-PS score of 0 or 1, were independent predictors of long-term survival. Conclusions: Pretreatment serum albumin levels may be useful for predicting long-term survival in R/M HNSCC patients treated with nivolumab.
摘要：
背景：Nivolumab已被证明可以改善复发和转移性头颈部鳞状细胞癌（R/MHNSCC）患者的总体生存率（OS）。然而,在这些患者中,需要确定与长期生存(超过2年)相关的因素.这项研究调查了接受纳武单抗治疗的R/MHNSCC患者的治疗因素与长期生存之间的关系。方法：回顾性分析49例接受纳武单抗治疗的R/MHNSCC患者。基线特征，临床资料,和生存结局进行评估。进行单变量和多变量分析以确定与长期生存（OS≥2年）相关的因素。结果：整个队列的中位OS为11.0个月，2年生存率为34.7%。长期幸存者（OS≥2年）的东部肿瘤协作组（ECOG）表现状态（PS）评分为0或1，血清白蛋白水平≥3.5g/dL的患者比例明显更高，与非长期幸存者相比，中性粒细胞与嗜酸性粒细胞的比率（NER）<32.0。在多变量分析中，血清白蛋白水平≥3.5g/dL，除了ECOG-PS评分为0分或1分外,它们也是长期生存的独立预测因子.结论：治疗前血清白蛋白水平可能有助于预测接受纳武单抗治疗的R/MHNSCC患者的长期生存。
